Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells

[1]  Tongsheng Chen,et al.  Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells. , 2014, Cellular signalling.

[2]  Tongsheng Chen,et al.  Resveratrol protects rabbit articular chondrocyte against sodium nitroprusside-induced apoptosis via scavenging ROS , 2014, Apoptosis.

[3]  O. Abdel-Rahman,et al.  Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. , 2014, Critical reviews in oncology/hematology.

[4]  C. Belka,et al.  Dihydroartemisinin is a Hypoxia-Active Anti-Cancer Drug in Colorectal Carcinoma Cells , 2014, Front. Oncol..

[5]  S. Thorgeirsson,et al.  SnapShot: Hepatocellular carcinoma. , 2014, Cancer cell.

[6]  H. Peh,et al.  Artemisinins: pharmacological actions beyond anti-malarial. , 2014, Pharmacology & therapeutics.

[7]  Tongsheng Chen,et al.  Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine , 2014, Apoptosis.

[8]  Zeeshan Gillani,et al.  Effect of HA14‐1 on Apoptosis‐Regulating Proteins in HeLa Cells , 2014, Chemical biology & drug design.

[9]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[10]  L. Dawson,et al.  Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. , 2013, International journal of radiation oncology, biology, physics.

[11]  Zhe Zhang,et al.  Anti-cancer activity of DHA on gastric cancer—an in vitro and in vivo study , 2013, Tumor Biology.

[12]  Tongsheng Chen,et al.  Artemisinin induces A549 cell apoptosis dominantly via a reactive oxygen species-mediated amplification activation loop among caspase-9, -8 and -3 , 2013, Apoptosis.

[13]  Tongsheng Chen,et al.  Ionizing Radiation Potentiates Dihydroartemisinin-Induced Apoptosis of A549 Cells via a Caspase-8-Dependent Pathway , 2013, PloS one.

[14]  A. Gasbarrini,et al.  Cost‐effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma , 2013, Hepatology.

[15]  Narendra Singh,et al.  Development of artemisinin compounds for cancer treatment , 2013, Investigational New Drugs.

[16]  Tongsheng Chen,et al.  Artesunate induces apoptosis via a Bak‐mediated caspase‐independent intrinsic pathway in human lung adenocarcinoma cells , 2012, Journal of cellular physiology.

[17]  Tao Chen,et al.  Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1 , 2012, PloS one.

[18]  Jin-jian Lu,et al.  Dihydroartemisinin-induced inhibition of proliferation in BEL-7402 cells: an analysis of the mitochondrial proteome. , 2012, Molecular medicine reports.

[19]  G. Wondrak,et al.  The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis , 2012, Investigational New Drugs.

[20]  J. Yun,et al.  Histone Deacetylase Inhibitors Facilitate Dihydroartemisinin-Induced Apoptosis in Liver Cancer In Vitro and In Vivo , 2012, PloS one.

[21]  B. Gillissen,et al.  Disruption of the VDAC2–Bak interaction by Bcl-xS mediates efficient induction of apoptosis in melanoma cells , 2012, Cell Death and Differentiation.

[22]  J. Yun,et al.  Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. , 2012, Biochemical pharmacology.

[23]  Tongsheng Chen,et al.  Resveratrol induces apoptosis via a Bak-mediated intrinsic pathway in human lung adenocarcinoma cells. , 2012, Cellular signalling.

[24]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[25]  Tongsheng Chen,et al.  Dihydroarteminsin-Induced Apoptosis is not Dependent on the Translocation of Bim to the Endoplasmic Reticulum in Human Lung Adenocarcinoma Cells , 2012, Pathology & Oncology Research.

[26]  M. Wei,et al.  Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug , 2011, Journal of biomedicine & biotechnology.

[27]  D. Green,et al.  A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.

[28]  Jian Li,et al.  Dihydroartemisinin induces endoplasmic reticulum stress-mediated apoptosis in HepG2 human hepatoma cells. , 2011, Tumori.

[29]  T. Efferth,et al.  Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells , 2011, Molecular Cancer Therapeutics.

[30]  T. Uzu,et al.  SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. , 2011, Free radical biology & medicine.

[31]  Xianglin Shi,et al.  Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo , 2011, Apoptosis.

[32]  Ye Ji,et al.  Anti-tumor effects of dihydroartemisinin on human osteosarcoma , 2011, Molecular and Cellular Biochemistry.

[33]  Tongsheng Chen,et al.  The JNK inhibitor SP600125 enhances dihydroartemisinin‐induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells , 2010, FEBS letters.

[34]  Lewis R. Roberts,et al.  Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.

[35]  C. Belka,et al.  Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway , 2010, Molecular Cancer Therapeutics.

[36]  Tongsheng Chen,et al.  Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques. , 2010, Journal of biomedical optics.

[37]  R. Kong,et al.  Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. , 2010, Cancer letters.

[38]  G. Nilsson,et al.  Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis , 2010, Cell Death and Disease.

[39]  J. Neuzil,et al.  α-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels , 2010, Apoptosis.

[40]  P. G. Rao,et al.  Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. , 2010, Chemical Society reviews.

[41]  Osamu Takeuchi,et al.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. , 2009, Molecular cell.

[42]  S. Dufort,et al.  Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells , 2009, Molecular Cancer Therapeutics.

[43]  G. Firestone,et al.  Anticancer activities of artemisinin and its bioactive derivatives , 2009, Expert Reviews in Molecular Medicine.

[44]  E. Arısan,et al.  Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. , 2009, Carcinogenesis.

[45]  Hui Wang,et al.  Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action , 2008, Clinical Cancer Research.

[46]  Tao Chen,et al.  Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy , 2008, Journal of cellular and molecular medicine.

[47]  F. Sinicrope,et al.  BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. , 2008, Cancer research.

[48]  V. Graupner,et al.  Activation of the mitochondrial death pathway is commonly mediated by a preferential engagement of Bak , 2008, Oncogene.

[49]  A. Strasser,et al.  In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute , 2008, Cell Death and Differentiation.

[50]  S. Fan,et al.  Dihydroartemisinin is an inhibitor of ovarian cancer cell growth , 2007, Acta Pharmacologica Sinica.

[51]  W. Hou,et al.  Functional Linkage between NOXA and Bim in Mitochondrial Apoptotic Events* , 2007, Journal of Biological Chemistry.

[52]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[53]  A. Strasser,et al.  Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction , 2006, The Journal of experimental medicine.

[54]  Seung-Wook Ryu,et al.  JNK- and p38 Kinase-mediated Phosphorylation of Bax Leads to Its Activation and Mitochondrial Translocation and to Apoptosis of Human Hepatoma HepG2 Cells* , 2006, Journal of Biological Chemistry.

[55]  J. Prieto,et al.  New therapies for hepatocellular carcinoma , 2006, Oncogene.

[56]  Lin Chen,et al.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.

[57]  M. V. Heiden,et al.  Caspase-9 is activated in a cytochrome c-independent manner early during TNFα-induced apoptosis in murine cells , 2003, Cell Death and Differentiation.

[58]  Hiroaki Kawasaki,et al.  Confirmation by FRET in individual living cells of the absence of significant amyloid β-mediated caspase 8 activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[60]  R. Millikan,et al.  The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. , 2001, Gastroenterology.

[61]  X. Qu,et al.  Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. , 2013, International journal of molecular medicine.

[62]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[63]  M. Peck-Radosavljevic,et al.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.